News
AGEN
--
0.00%
--
William Blair Thinks Agenus’ Stock is Going to Recover
William Blair analyst Matt Phipps maintained a Buy rating on Agenus (AGEN) on April 12. The company's shares closed last Thursday at $2.66, close to its
SmarterAnalyst · 1d ago
Dosing underway in Agenus' early-stage study of iNKT cell therapy
Agenus (AGEN) announces the dosing of the first cancer patient in Phase 1 clinical trial of agenT-797, an allogeneic iNKT cell therapy, through its subsidiary, AgenTus Therapeutics. The Phase 1 trial
Seekingalpha · 2d ago
Agenus Doses First Cancer Patient With iNKT Cell Therapy
Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today
Benzinga · 2d ago
Agenus presents new clinical responses for AGEN1181 at AACR
Agenus (AGEN) announces new clinical data on AGEN1181 at the American Association for Cancer Research ((AACR)) Annual Meeting. The company showcased the optimal performance of AGEN1181 in relevant models. The
Seekingalpha · 5d ago
New Clinical Responses for AGEN1181 Presented at AACR
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASD...
GlobeNewswire · 6d ago
Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer
, /PRNewswire/ -- The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in in 2020. Overall, lung and bronchus cancer is...
PR Newswire - PRF · 04/09 13:00
Agenus to Participate in Webcast Hosted by William Blair on AGEN1181 and Balstilimab AACR Presentations
LEXINGTON, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infectio...
GlobeNewswire · 04/06 13:30
The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight
Biotech stocks ended the holiday-shortened week ended April 1 in the green, catalyzed by the broader market rebound and a slew of company-specific news flow. Buoyed by hopes of a U.S.
Benzinga · 04/03 13:11
4 Penny Stocks To Buy Now With Price Targets Up To 302%
Apr 02, 2021 (Penny Stocks via COMTEX) -- Analysts Say Buy These Penny Stocks; Do You Agree? Many have taken an interest in penny stocks over the last year....
Penny Stocks · 04/02 20:09
Agenus Stock Is Estimated To Be Modestly Undervalued
GuruFocus News · 03/30 12:32
Therapeutic Vaccines Market to Witness a Moderate CAGR During 2021-2029; Increasing Prevalence of Chronic & Infectious Diseases to Create Opportunities for Market Growth
Mar 17, 2021 (AmericaNewsHour) -- Research Nester published a report titled "Therapeutic Vaccines Market: Global Demand Analysis & Opportunity Outlook...
AmericaNewsHour · 03/17 12:11
10-K: AGENUS INC
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Overview Agenus Inc. (including...
Edgar Online - (EDG = 10Q, 10K) · 03/16 20:53
Agenus (AGEN) Gets a Buy Rating from Jefferies
In a report released yesterday, Biren Amin from Jefferies maintained a Buy rating on Agenus (AGEN), with a price target of $7.00. The company's shares
SmarterAnalyst · 03/16 12:26
B.Riley Financial Maintains Their Buy Rating on Agenus (AGEN)
B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Agenus (AGEN) today and set a price target of $8.00. The company's shares closed last
SmarterAnalyst · 03/15 19:35
DJ Agenus Inc. CEO Garo Armen on Q4 2020 Results -- Earnings Call Transcript >AGEN
Dow Jones · 03/15 17:44
Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 03/15 14:05
Agenus: Q4 Earnings Insights
Shares of Agenus (NASDAQ:AGEN) moved higher by 0.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 9.09% year over year to ($0.20), which beat the estimate of ($0.22). Revenue of $31,265,000 decrea...
Benzinga · 03/15 13:25
Agenus shares rise after Q4 results, pipeline update
Agenus (AGEN) shares rise nearly 5% premarket after the company posted fourth-quarter results that beat Wall Street estimates, helped partly by upfront license fee gained from recent transactions.The company posted fourth-quarter revenue of $31.26M,
Seekingalpha · 03/15 12:07
Agenus EPS beats by $0.02, beats on revenue
Agenus (AGEN): Q4 GAAP EPS of -$0.20 beats by $0.02.Revenue of $31.26M (-9.4% Y/Y) beats by $15.03M.Press Release
Seekingalpha · 03/15 11:52
Agenus Q4 EPS $(0.20) Beats $(0.22) Estimate
Agenus (NASDAQ:AGEN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.22) by 9.09 percent. This is a 9.09 percent increase over losses of $(0.22) per share from the same
Benzinga · 03/15 11:46
Webull provides a variety of real-time AGEN stock news. You can receive the latest news about Agenus through multiple platforms. This information may help you make smarter investment decisions.
About AGEN
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.